CMMB

Healthcare Biotechnology

Chemomab Therapeutics Ltd.

$1.43

+0.12 +9.16% today

Price History

Not enough data

Key Stats

Market Cap

10.48M

Avg Volume

161,607

EPS

-$0.96

52W High

$3.58

52W Low

$1.05

Div. Yield

0.0%

Analyst Ratings

Strong Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-47.67

P/B Ratio

1.19

EV/EBITDA

-0.47

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(82.2%)

Return on Assets

(46.3%)

Liquidity & Leverage

Current Ratio

6.41

Quick Ratio

6.41

Total Cash

6.69M

Total Debt

About

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.